Literature DB >> 35152301

Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity.

Byung Sik Kim1, In-Hwa Park2, A-Hyeon Lee2, Hyun-Jin Kim1, Young-Hyo Lim3, Jeong-Hun Shin4.   

Abstract

The induction of endoplasmic reticulum (ER) stress has been reported as a key contributor to the cardiotoxicity of doxorubicin. Previous in vitro and in vivo studies suggest that sacubitril/valsartan, a novel angiotensin receptor-neprilysin inhibitor, could be effective against doxorubicin-induced cardiotoxicity. However, the precise mechanisms are not fully understood. Therefore, we investigated whether the cardioprotective effects of sacubitril/valsartan are associated with ER stress modulation in a rat model of doxorubicin-induced cardiotoxicity. Male Sprague-Dawley rats were treated with intraperitoneal injections of doxorubicin (15 mg/kg; cumulative) or saline for 3 weeks. From the day before the first treatment, control animals were gavaged daily with water (n = 8), whereas doxorubicin-treated animals were gavaged daily with water (n = 8) or sacubitril/valsartan (60 mg/kg/day; n = 8) for 6 weeks. Echocardiography was performed 6 weeks after the initiation of doxorubicin. In addition, serum troponin I and N-terminal brain natriuretic peptide levels were determined, and the extent of apoptosis and protein levels related to ER stress in the cardiac tissue and doxorubicin-treated H9c2 cardiomyocytes were analyzed. Sacubitril/valsartan significantly reduced doxorubicin-induced cardiac dysfunction and apoptosis in the myocardium. In addition, sacubitril/valsartan significantly downregulated the expression levels of proteins related to apoptosis and ER stress, including BAX, caspase 3, GRP78, PERK, IRE-1α, ATF-6, eIF-2α, ATF-4, and CHOP, in the myocardium of a rat model of doxorubicin-induced cardiotoxicity in vivo and doxorubicin-treated H9c2 cardiomyocytes in vitro. Sacubitril/valsartan significantly alleviated doxorubicin-induced cardiotoxicity, which may be associated with the reduction of ER stress.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cardiotoxicity; Doxorubicin; Endoplasmic reticulum stress; Sacubitril/valsartan

Mesh:

Substances:

Year:  2022        PMID: 35152301     DOI: 10.1007/s00204-022-03241-1

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  30 in total

Review 1.  Cell death induced by endoplasmic reticulum stress.

Authors:  Raffaella Iurlaro; Cristina Muñoz-Pinedo
Journal:  FEBS J       Date:  2015-12-19       Impact factor: 5.542

2.  Endoplasmic Reticulum (ER) Stress Response Failure in Diseases.

Authors:  Kashi Raj Bhattarai; Manoj Chaudhary; Hyung-Ryong Kim; Han-Jung Chae
Journal:  Trends Cell Biol       Date:  2020-06-16       Impact factor: 20.808

3.  Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Giulia Bacchiani; Ines Tedeschi; Carlo A Meroni; Fabrizio Veglia; Maurizio Civelli; Giuseppina Lamantia; Nicola Colombo; Giuseppe Curigliano; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2015-05-06       Impact factor: 29.690

4.  B-type natriuretic peptide attenuates endoplasmic reticulum stress in H9c2 cardiomyocytes underwent hypoxia/reoxygenation injury under high glucose/high fat conditions.

Authors:  Pan Chang; Mingyang Zhang; Xiaomeng Zhang; Guohua Li; Haiyan Hu; Juan Wu; Xihui Wang; Zihua Yang; Jing Zhang; Weiguo Chen; Minggang Ren; Xin Li; Miaozhang Zhu; Baoying Chen; Jun Yu
Journal:  Peptides       Date:  2018-04-22       Impact factor: 3.750

5.  Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.

Authors:  Eric J Chow; Barbara L Asselin; Cindy L Schwartz; David R Doody; Wendy M Leisenring; Sanjeev Aggarwal; K Scott Baker; Smita Bhatia; Louis S Constine; David R Freyer; Steven E Lipshultz; Saro H Armenian
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

6.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).

Authors:  Xavier Bosch; Montserrat Rovira; Marta Sitges; Ariadna Domènech; José T Ortiz-Pérez; Teresa M de Caralt; Manuel Morales-Ruiz; Rosario J Perea; Mariano Monzó; Jordi Esteve
Journal:  J Am Coll Cardiol       Date:  2013-04-10       Impact factor: 24.094

7.  Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Authors:  Jessie Gu; Adele Noe; Priya Chandra; Suliman Al-Fayoumi; Monica Ligueros-Saylan; Ramesh Sarangapani; Suzanne Maahs; Gary Ksander; Dean F Rigel; Arco Y Jeng; Tsu-Han Lin; Weiyi Zheng; William P Dole
Journal:  J Clin Pharmacol       Date:  2009-11-23       Impact factor: 3.126

8.  Chemical Endoplasmic Reticulum Chaperone Alleviates Doxorubicin-Induced Cardiac Dysfunction.

Authors:  Hai Ying Fu; Shoji Sanada; Takashi Matsuzaki; Yulin Liao; Keiji Okuda; Masaki Yamato; Shota Tsuchida; Ryo Araki; Yoshihiro Asano; Hiroshi Asanuma; Masanori Asakura; Brent A French; Yasushi Sakata; Masafumi Kitakaze; Tetsuo Minamino
Journal:  Circ Res       Date:  2016-02-01       Impact factor: 17.367

9.  Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity.

Authors:  Nabil E Boutagy; Attila Feher; Daniel Pfau; Zhao Liu; Nicole M Guerrera; Lisa A Freeburg; Sydney J Womack; Abigail C Hoenes; Caroline Zeiss; Lawrence H Young; Francis G Spinale; Albert J Sinusas
Journal:  JACC CardioOncol       Date:  2020-12-22

Review 10.  The C/EBP Homologous Protein (CHOP) Transcription Factor Functions in Endoplasmic Reticulum Stress-Induced Apoptosis and Microbial Infection.

Authors:  Hai Hu; Mingxing Tian; Chan Ding; Shengqing Yu
Journal:  Front Immunol       Date:  2019-01-04       Impact factor: 7.561

View more
  3 in total

Review 1.  Molecular mechanisms of sacubitril/valsartan in cardiac remodeling.

Authors:  Nor Hidayah Mustafa; Juriyati Jalil; Satirah Zainalabidin; Mohammed S M Saleh; Ahmad Yusof Asmadi; Yusof Kamisah
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

2.  Effects of Valsartan on LN, FN, MDA, Renal Tissue Fibrosis, and Inflammatory Infiltration in DN Rats.

Authors:  Yongting Qin; Gugangzhi Li; Juan Chen; Shuangli Qin; Shizhen Wang; Shanshan Chen
Journal:  Contrast Media Mol Imaging       Date:  2022-08-04       Impact factor: 3.009

3.  Tunicamycin-Induced Endoplasmic Reticulum Stress Damages Complex I in Cardiac Mitochondria.

Authors:  Qun Chen; Jeremy Thompson; Ying Hu; Edward J Lesnefsky
Journal:  Life (Basel)       Date:  2022-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.